These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 25335749)

  • 21. Nerve growth factor (NGF): a potential urinary biomarker for overactive bladder syndrome (OAB)?
    Seth JH; Sahai A; Khan MS; van der Aa F; de Ridder D; Panicker JN; Dasgupta P; Fowler CJ
    BJU Int; 2013 Mar; 111(3):372-80. PubMed ID: 23444927
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The role of urinary nerve growth factor for the diagnosis and assessment of the biofeedback success in children with dysfunctional voiding.
    Ergin G; Kibar Y; Ebiloğlu T; Irkılata HC; Kopru B; Kaya E; Uyanık M; Tapan S; Dayanc MM
    J Pediatr Urol; 2016 Apr; 12(2):118.e1-6. PubMed ID: 26701107
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Urinary nerve growth factor level could be a potential biomarker for diagnosis of overactive bladder.
    Liu HT; Kuo HC
    J Urol; 2008 Jun; 179(6):2270-4. PubMed ID: 18423678
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Functional characterization of a chronic cyclophosphamide-induced overactive bladder model in mice.
    Boudes M; Uvin P; Kerselaers S; Vennekens R; Voets T; De Ridder D
    Neurourol Urodyn; 2011 Nov; 30(8):1659-65. PubMed ID: 21717507
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Nerve Growth Factor Levels are Associated with Overactive Bladder Symptoms and Long-Term Treatment Outcome after Transurethral Resection of the Prostate in Patients with Benign Prostatic Hyperplasia.
    Hu H; Zhang W; Liu X; Wang H; Fang Z; Liang C; Wang T; Xu K
    J Urol; 2018 Sep; 200(3):620-625. PubMed ID: 29630981
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Sensory Hyperinnervation Distinguishes Bladder Pain Syndrome/Interstitial Cystitis from Overactive Bladder Syndrome.
    Regauer S; Gamper M; Fehr MK; Viereck V
    J Urol; 2017 Jan; 197(1):159-166. PubMed ID: 27378135
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Urinary biomarkers in patients with detrusor underactivity with and without bladder function recovery.
    Chen SF; Jiang YH; Kuo HC
    Int Urol Nephrol; 2017 Oct; 49(10):1763-1770. PubMed ID: 28770419
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The overlap and distinction of self-reported symptoms between interstitial cystitis/bladder pain syndrome and overactive bladder: a questionnaire based analysis.
    Lai HH; Vetter J; Jain S; Gereau RW; Andriole GL
    J Urol; 2014 Dec; 192(6):1679-85. PubMed ID: 24907443
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Decrease of urinary nerve growth factor but not brain-derived neurotrophic factor in patients with interstitial cystitis/bladder pain syndrome treated with hyaluronic acid.
    Jiang YH; Liu HT; Kuo HC
    PLoS One; 2014; 9(3):e91609. PubMed ID: 24614892
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of inflammatory urine markers in patients with interstitial cystitis and overactive bladder.
    Furuta A; Yamamoto T; Suzuki Y; Gotoh M; Egawa S; Yoshimura N
    Int Urogynecol J; 2018 Jul; 29(7):961-966. PubMed ID: 29372285
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Changes in nerve growth factor level and symptom severity following antibiotic treatment for refractory overactive bladder.
    Vijaya G; Cartwright R; Derpapas A; Gallo P; Fernando R; Khullar V
    Int Urogynecol J; 2013 Sep; 24(9):1523-8. PubMed ID: 23376905
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Editorial comment on: Urinary nerve growth factor levels are elevated in patients with detrusor overactivity and decreased in responders to detrusor botulinum toxin-A injection.
    Novara G
    Eur Urol; 2009 Oct; 56(4):706-7. PubMed ID: 18472211
    [No Abstract]   [Full Text] [Related]  

  • 33. Could urinary nerve growth factor be a biomarker for overactive bladder? A meta-analysis.
    Sheng W; Zhang H; Ruth KH
    Neurourol Urodyn; 2017 Sep; 36(7):1703-1710. PubMed ID: 28102552
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Correlation of urinary nerve growth factor level with pathogenesis of overactive bladder.
    Yokoyama T; Kumon H; Nagai A
    Neurourol Urodyn; 2008; 27(5):417-20. PubMed ID: 17924444
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Urinary nerve growth factor levels are elevated in patients with overactive bladder and do not significantly increase with bladder distention.
    Liu HT; Kuo HC
    Neurourol Urodyn; 2009; 28(1):78-81. PubMed ID: 19089891
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Increased urine and serum nerve growth factor levels in interstitial cystitis suggest chronic inflammation is involved in the pathogenesis of disease.
    Liu HT; Kuo HC
    PLoS One; 2012; 7(9):e44687. PubMed ID: 23028581
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Urinary prostaglandin E₂ was increased in patients with suprapontine brain diseases, and associated with overactive bladder syndrome.
    Yamauchi H; Akino H; Ito H; Aoki Y; Nomura T; Yokoyama O
    Urology; 2010 Nov; 76(5):1267.e13-9. PubMed ID: 20800884
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Urinary nerve growth factor in children with overactive bladder: a promising, noninvasive and objective biomarker.
    Oktar T; Kocak T; Oner-Iyidogan Y; Erdem S; Seyithanoglu M; Ziylan O; Kocak H
    J Pediatr Urol; 2013 Oct; 9(5):617-21. PubMed ID: 22789557
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Novel biomarkers for overactive bladder.
    Cartwright R; Afshan I; Derpapas A; Vijaya G; Khullar V
    Nat Rev Urol; 2011 Mar; 8(3):139-45. PubMed ID: 21321572
    [TBL] [Abstract][Full Text] [Related]  

  • 40. NGF and HB-EGF: potential biomarkers that reflect the effects of fesoterodine in patients with overactive bladder syndrome.
    Kim SR; Moon YJ; Kim SK; Bai SW
    Yonsei Med J; 2015 Jan; 56(1):204-11. PubMed ID: 25510766
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.